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Abstract. Inhibition of epidermal growth factor receptor 
(EGFR) signaling has emerged as a novel therapeutic strategy 
for the treatment of oral squamous cell carcinoma (OSCC). 
The EGFR-directed inhibitor cetuximab is currently the only 
approved targeted therapy for the treatment of OSCC. EGFR 
status may affect the patient response to cetuximab treatment. 
In the present study, via analysis of the immunomarker for 
EGFR, it was revealed that 58.3% of the total cases investigated 
stained positively for EGFR expression, and furthermore, that 
invasiveness was inversely correlated with EGFR expression. 
Expression levels of EGFR were quantified, and the correla-
tion between EGFR expression and cetuximab sensitivity was 
investigated using three varying grades of invasive human 
OSCC line. EGFR expression in high-grade invasive cells was 
significantly downregulated compared with that of low‑grade 
invasive cells. There was no significant antiproliferative effect 
in the high-grade invasive cells treated with various concentra-
tions of cetuximab. The EMT-associated genes, N-cadherin, 
vimentin and Snail, were upregulated in the high-grade invasive 
cells. The low-grade invasive cells exhibited characteristics of 
typical epithelial cells, including the expression of E-cadherin 
and absence of the expression of N-cadherin, vimentin and 
Snail. Transforming growth factor-β induced low-grade inva-
sive cells to undergo an epithelial-mesenchymal transition 
(EMT)-associated gene switch, which resulted in low levels of 
EGFR expression. The results of the present study suggested 
that loss of EGFR expression in OSCC was associated with 
EMT, and may have functional implications with regard to 
tumor invasiveness and the resistance to cetuximab treatment.
Introduction
Epidermal growth factor receptor (EGFR/ErbB1/HER1) 
overexpression is found in the majority of oral squamous cell 
carcinoma (OSCC) tumors, and associations have been made 
between increased expression levels and an aggressive pheno-
type, poor prognosis and resistance to anticancer therapy (1). 
A number of anti-EGFR antibodies (including cetuximab and 
panitumumab) and small molecule tyrosine kinase inhibitors 
(including gefitinib and erlotinib), which target EGFR, have 
been developed (2). However, only the monoclonal antibody 
cetuximab (Erbitux®) is currently approved for the treatment of 
advanced OSCC (3). Cetuximab therapy has been observed to 
be effective in the treatment of recurrent and metastatic OSCC, 
as a first‑line treatment in combination with platinum‑based 
chemotherapy (4-7), and as a second-line therapy in patients 
exhibiting platinum-resistant disease (8-10). In clinical practice, 
EGFR expression may be evaluated by utilizing a standardized 
immunohistochemistry (IHC) assay, which is designed to assess 
cell membrane staining (11). IHC studies have demonstrated 
EGFR overexpression in >75% of the total analyzed OSCC 
cases, demonstrating values of 73.42% (12), 87.5% (13) and 
72% (14). However, the cetuximab response rate is typically not 
greater than 20% (15), therefore the role of EGFR expression 
as a predictor of patient response to EGFR-targeted therapeutic 
agents remains to be fully elucidated.
The sensitivity of certain tumors to cetuximab may be 
explained by the presence of mutations in the EGFR tyrosine 
kinase domain (16,17). However, such mutations are rare 
in OSCC (18). Thus, there is a requirement to elucidate the 
mechanisms underlying the differential drug response of 
cancer cells with wild-type EGFR. This may assist with the 
identification of patients who may respond and clinically 
benefit from cetuximab treatment, and furthermore may aid 
in the development of novel therapeutic strategies, in order to 
circumvent the de novo or acquired resistance of tumors to 
cetuximab. Tumor resistance mechanisms to cetuximab may 
also be targetable, and may thus present a potential opportu-
nity to increase the efficacy of cetuximab therapy. In general, 
tumors that are frequently therapy-resistant may originate 
from tumor cells exhibiting an epithelial-mesenchymal 
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transition (EMT) phenotype (19). During EMT, epithelial 
cells lose their characteristic polarity and cell-cell contact, 
and acquire a more migratory mesenchymal phenotype (20). 
EMT has additionally been demonstrated to promote stem 
cell properties. Furthermore, the in vitro sensitivity of head 
and neck cancer cell lines to anticancer agents has been 
revealed to be affected by EMT-associated gene expres-
sion (21,22).
In the present study, the expression of EGFR in human 
OSCC tissues and cell lines was evaluated and the association 
between EGFR expression and clinicopathological features 
in these tissues and cells was investigated. Furthermore, the 
OSCC cells and tissues were analyzed with regard to their 
EMT characteristics, and the OSCC cell lines were also exam-
ined for their intrinsic sensitivity to cetuximab treatments.
Materials and methods
Tissue samples. The present study was approved by the Ethics 
Committee of the Kanazawa University Graduate School of 
Medical Science (Kanazawa, Japan) and written informed 
consent was obtained from each patient. The subjects 
consisted of 24 patients exhibiting primary OSCC who under-
went surgical resection of their tumors at the Department 
of Oral and Maxillofacial Surgery at Kanazawa University 
Hospital (Kanazawa, Japan), between 1998 and 2008. The 
patients ranged from 43-89 years old (mean ± standard devia-
tion, 64.4±11.2 years). The tumor-node-metastasis categories 
were assigned according to the Union for International Cancer 
Control system (23). The tumor differentiation grade was 
determined according to the classification criteria proposed 
by the World Health Organization (24). The mode of tumor 
invasion was assessed according to the criteria proposed by 
Yamamoto et al (25).
IHC. Each specimen was fixed in 10% buffered formalin 
(Sigma-Aldrich Japan K.K., Tokyo, Japan) and subsequently 
embedded in paraffin for the preparation of serial sections. 
Immunohistochemical staining was performed using an EGFR 
pharmDx™ kit (K1492; Dako Japan K.K., Tokyo, Japan). The 
specificity of the staining was confirmed using Universal 
Negative Control for IS-Series Rabbit Primary Antibodies (cat 
no. IS600; Dako Japan K.K.) rather than primary antibody as 
a negative control. The images of 3 separate stained regions 
were captured under a light microscope at x100 magnification 
and evaluated based on the number of stained tumor cells, 
according to the method described by Bernardes et al (26). 
EGFR expression was evaluated based on the extent of immu-
nolabeling in the tumor cell membranes, and was classified on 
a 4-point scale as follows: 0, no labeling or labeling in <10% of 
tumor cells; 1, weak labeling, homogeneous or patchy, in >10% 
of tumor cells; 2, moderate labeling, homogeneous or patchy, 
in >10% of tumor cells; and 3, intense labeling, homogeneous 
or patchy, in >10% of tumor cells. The initial scores were 
subsequently grouped into two final groups: Low expression 
(0 or 1) and high expression (2 or 3).
Cell lines. A total of 3 human OSCC cell lines, established 
from tumor biopsies with varying grades of invasive ability, 
were used: OSC-20 and OSC-19, low-grade invasive cells, 
and HOC313, high-grade invasive cells. OSC-20 is a cell line 
derived from a 58-year-old female exhibiting tongue cancer 
that metastasized to the cervical lymph nodes (27). OSC-19 
was derived from a 61-year-old male exhibiting tongue cancer 
that metastasized to the cervical lymph nodes (28). HOC313 
was de rived from a 51-year-old female exhibiting squamous 
cell carcinoma (involving the mandibular gingiva and oral 
floor) that metastasized to the cervical lymph nodes (29). 
Additionally, normal human dermal fibroblasts (NHDFs; 
cat. no. PCS-201-010), obtained from the American Type 
Culture Collection (Manassas, VA, USA), served as a control.
Proliferation assay and cetuximab sensitivity. A 3-(4, 5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
was used in order to investigate the ability of cetuximab to 
inhibit the proliferation of the 3 OSCC lines (OSC-19, OSC-20 
and HOC313) in vitro. Initially, 2,500 cells/well were cultured 
in Dulbecco's modified Eagle's medium (DMEM; D7440; 
Sigma-Aldrich Japan K.K.) supplemented with Hyclone™ 10% 
fetal bovine serum (FBS; GE Healthcare, Logan, UT, USA), 
in 96-well tissue culture plates. Following 24 h of culture, the 
cells were treated with varying concentrations of cetuximab 
(Erbitux®; Merck Serono Co., Ltd., Tokyo, Japan; 0, 0.005 and 
0.01 µg/ml) diluted in DMEM supplemented with 2% FBS. 
In order to measure the number of metabolically active cells 
following 24, 48 and 72 h of incubation, an MTT assay was 
performed and the results were quantified according to the 
manufacturer's protocols. The optical density at 450 nm was 
measured using a microplate reader (iMark Microplate Absor-
bance Reader; Bio-Rad Laboratories, Inc., Hercules, CA, USA).
RNA extraction, complementary DNA (cDNA) synthesis and 
quantitative polymerase chain reaction (qPCR). The messenger 
RNA (mRNA) levels of EGFR, E-cadherin, vimentin, Twist 
and Snail were analyzed using a Rotor-Gene Q 2plex HRM 
System (9001560; Qiagen GmbH, Hilden, Germany) with 
FAM/ZEN/IBFQ probes (DNA sequence unopened; Integrated 
DNA Technologies, Inc., Coralville, IA, USA). Total RNA was 
extracted using the RNeasy Protect Mini kit (74124; Qiagen 
GmbH), and cDNA was obtained by utilizing the PrimeScript 
1st Strand cDNA Synthesis kit (6110A; Takara Bio, Inc., Otsu, 
Japan). All reactions and conditions were performed according 
to the manufacturer's protocols. Ribosomal RNA (18S) was 
amplified as an internal standard using HEX/ZEN/IBFQ 
probes (DNA sequence unopened; Integrated DNA Tech-
nologies, Inc.). Data were analyzed using the comparative Cq 
method, which presented the data as a fold-change in expres-
sion level relative to a calibrator sample (in the present case, 
the mean expression of the 3 replicates of the NHDF cell line).
Enzyme‑linked immunosorbent assay (ELISA). For 
enzyme-linked immunosorbent assay analysis of EGFR and 
phosphorylated EGFR, 3 human oral cancer cell lines (OSC-20, 
OSC-19 and HOC313) were cultured. Following incubation 
for 24 h, the cells were seeded into a 96-well tissue culture 
plate (BD Biosciences, Tokyo, Japan) and fixed for 5 min by 
4% formaldehyde solution (Sigma-Aldrich Japan K.K.) in 
phosphate-buffered saline (Sigma-Aldrich Japan K.K.). The 
expression levels of EGFR and phosphorylated EGFR were 
quantified using the human EGFR In‑Cell ELISA kit (ab126419; 
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Abcam, Cambridge, MA, USA) according to the manufacturer's 
protocols. The data were presented as a fold-change in expres-
sion level relative to the mean expression of the 3 replicates of 
the NHDF cell line.
EMT induction. In order to induce EMT, OSC-20 and OSC-19 
cells were seeded at 70% conﬂuence into a 10‑cm plastic dish 
(BD Biosciences) and cultured for 48 and 72 h in DMEM to 
induce EMT (Sigma-Aldrich Japan K.K.)with 0.5% FBS. 
Recombinant human transforming growth factor-β1 (240-B; 
R&D Systems, Inc., Minneapolis, MN, USA) was added at a 
final concentration of 5 ng/ml.
Statistical analysis. Statistical analysis was performed using 
JMP® version 9.0 (SAS Institute, Inc., Cary, NC, USA). The 
association between EGFR protein expression and clinicopatho-
logical features was examined using Pearson's χ2 test. Data from 
the ELISA and MTT assays are presented as the mean ± stan-
dard error. Differences between groups were tested for statistical 
significance using the two‑tailed Mann‑Whitney U test. P<0.05 
was considered to indicate a statistically significant difference.
Results
EGFR expression is associated with certain clinicopathological 
features. EGFR expression was detected in the cell membrane 
and cytoplasm of the tumor cells (Fig. 1). According to the 
criteria for EGFR immunohistochemical evaluation (26), 58.3% 
(14/24) of the total cases investigated were positive for EGFR 
expression. Table I illustrates the correlations between EGFR 
expression and certain clinicopathological features. EGFR 
expression in high-grade invasive OSCC (mode of invasion, 
grade 4D) was significantly downregulated compared with that 
of low-grade invasive OSCC (mode of invasion, grades 3 and 4C; 
P=0.039). By contrast, EGFR expression did not correlate with 
tumor size (P=0.991), local recurrence (P=0.071) histological 
differentiation (P=0.137) or lymph node metastasis (P=0.456).
EGFR is differentially expressed in the 3 different grades of 
invasive OSCC cell lines. As demonstrated by immunohisto-
chemical analysis, only invasiveness (mode of invasion) was 
inversely correlated with the expression of EGFR (Table I). 
Therefore, EGFR expression in the 3 different grades of inva-
sive human OSCC lines (OSC-19, OSC-20 and HOC313) was 
analyzed at the mRNA and protein level using qPCR and ELISA, 
respectively. Data are presented as a fold-change relative to the 
mean of 3 replicates of the NHDF cell line (Fig. 2). Among 
the three OSCC cell lines (OSC-19, OSC-20 and HOC313), 
the EGFR mRNA expression level ranged from 0.7- to 3.7-fold 
higher compared with that of the NHDFs (Fig. 2A). The expres-
sion of EGFR mRNA in the 2 low-grade invasive cell lines 
(OSC-20 and OSC-19) was 3.7- and 2.3-fold higher compared 
with the NHDFs, respectively. The EGFR mRNA expression in 
the high-grade invasive cells (HOC313) was markedly reduced 
and similar to that of the NHDFs. By contrast, the 2 low-grade 
invasive cell lines (OSC-20 and OSC-19) possessed EGFR 
Table I. Correlation between EGFR expression and clinicopathological features of oral squamous cell carcinoma patients.
 EGFR expression
 ------------------------------------------------------------------------------------------
Clinicopathological feature High (n=14) Low (n=10) P-value
Tumor category   0.991
  T1   3 2
  T2   8 6
  T3   1 0
  T4   2 2
Node category   0.456
  Negative 13 7
  Positive   1 3
Local recurrence   0.071
  Negative 10 4
  Positive   4 6
Differentiation   0.137
  Well 10 7
  Moderate   3 0
  Poor   1 3
Mode of invasion, grade    0.039a
  3   7 1
  4C   5 3
  4D   2 6
aP<0.05. EGFR, epidermal growth factor receptor.
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protein expression levels 3.5- and 2.1-fold higher compared with 
those of the NHDFs, respectively (Fig. 2B). The high-grade 
invasive cells (HOC313) exhibited the lowest levels of EGFR 
protein expression. The quantities of phosphorylated EGFR 
were assessed in order to determine the activation status of 
EGFR. Expression levels of phosphorylated EGFR ranged from 
2.2- to 0.87-fold higher compared with those of the NHDFs 
(Fig. 2C). Expression patterns of phosphorylated EGFR were 
similar to the expression patterns of EGFR mRNA and protein.
Cetuximab sensitivity is dependent on OSCC invasiveness. 
In order to evaluate the significance of EGFR status in rela-
tion to cetuximab sensitivity, the cetuximab sensitivity of 
3 human OSCC lines exhibiting varying grades of invasive 
ability (OSC-19, OSC-20 and HOC313) was evaluated. Cells 
were seeded at clonal density, and the antiproliferative effects 
of cetuximab were determined using an MTT assay (Fig. 3). 
Antiproliferative effects of cetuximab were observed in the 
OSC-20 and OSC-19 cell lines. In the OSC-20 and OSC-19 cells 
(low-grade invasive OSCC), following incubation with cetux-
imab (0.005 µg/ml and 0.01 µg/ml) for 48 and 72 h, proliferation 
was significantly inhibited compared with non-treated cells 
(P<0.05). However, the varying concentrations of cetuximab 
exerted no significant antiproliferative effects on the HOC313 
cell line (P>0.05).
An EMT phenotype is detectable in the high‑grade inva‑
sive OSCC cell line. In order to evaluate whether EGFR 
expression was associated with the features of EMT, levels 
of N-cadherin, E-cadherin, vimentin and Snail were investi-
gated in 3 different invasive human OSCC cell lines (OSC-19, 
OSC-20 and HOC313; Fig. 4A). The expression levels of 
EMT-associated genes in the OSC-19 and HOC313 cells are 
presented as fold-changes relative to the OSC-20 cells. The 
HOC313 cells (high-grade invasive cells with loss of EGFR 
expression) exhibited a mesenchymal phenotype manifested 
through loss of E-cadherin and acquisition of N-cadherin, 
vimentin and Snail expression compared with the OSC-20 
and OSC-19 cell lines (Fig. 4A). In order to examine whether 
TGF-β altered the expression of the EMT-associated genes 
and EGFR, the 2 low-grade invasive cell lines (OSC-20 and 
OSC-19) were exposed to TGF-β (Fig. 4B). Expression levels 
are presented as fold differences relative to the control vehicle 
at 48 and 72 h, respectively. Serial examination of EMT 
Figure 2. EGFR expression in 3 varying grades of invasive human oral 
squamous cell carcinoma line. The OSC-19, OSC-20 and HOC313 cell lines 
were evaluated for variations in (A) EGFR mRNA, (B) EGFR protein and 
(C) pEGFR expression levels. Data are presented as a fold difference in 
expression level relative to the mean expression of the normal human dermal 




  CFigure 1. Immunohistochemical staining of EGFR in human OSCC tissues. 
(A) Positive immunoexpression of EGFR in OSCC. (B) Specificity of the 
staining was confirmed by using non‑immune antibody instead of primary 
antibody as a negative control. Scale bar, 100 µm. EGFR, epidermal growth 
factor receptor; OSCC, oral squamous cell carcinoma.
  A
  B
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markers (loss of E-cadherin and upregulation of N-cadherin, 
vimentin and Snail) over a specific time course (48 and 
72 h) revealed that TGF-β treatment induced EMT in the 
OSC-20 cells (Fig. 4B). By contrast, TGF-β was not effective 
in the induction of EMT in the OSC-19 cells. Notably, total 
EGFR mRNA in the OSC-20 and OSC-19 cells was reduced 
following EMT induction by TGF-β treatment.
Discussion
EGFR (a tyrosine kinase receptor from the ErbB family) is an 
oncogene that has been identified in a number of malignancies, 
including cancer of the breast, prostate, pulmonary system, 
bladder, and head and neck (30). EGFR is overexpressed and 
appears to be the dominant controlling factor underlying 
the malignant phenotype in head and neck squamous cell 
carcinomas, via adjustment of the molecules involved in 
invasive angiogenic and lymphangiogenic processes (12). By 
analyzing the immunomarker for EGFR in the present study, 
positive staining for EGFR expression was identified in 
58.3% of the total cases analyzed. The results of the present 
study were consistent with previously reported data (12-14). 
Furthermore, to the best of our knowledge, the present study 
demonstrated for the first time that invasiveness (mode of 
invasion) was inversely correlated with EGFR expression in 
OSCC patients. The present study also revealed that there 
Figure 3. Cetuximab sensitivity of 3 varying grades of invasive human oral 
squamous cell carcinoma line. (A) OSC-20, (B) OSC-19 and (C) HOC313 
cells were treated with various concentrations of cetuximab as indicated, 
and the antiproliferative effects of cetuximab treatment were determined by 
3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Each 
data point represents the mean of three independent experiments. Data are 
presented as standard deviations. Error bars correspond to the standard error. 
*P<0.05. O.D., optical density.
Figure 4. EGFR and EMT-associated gene expression in 3 varying grades 
of invasive human OSCC line. (A) Relative mRNA expression levels of 
EMT-associated genes, E-cadherin, N-cadherin, vimentin and Snail, in 
OSC-20, OSC-19 and HOC313 cell lines. The high-grade invasive OSCC 
cell line (HOC313) demonstrated upregulation of EMT-associated genes. 
Expression levels in OSC-19 and HOC313 are displayed as fold-changes 
relative to the expression levels in OSC-20. (B) Relative mRNA expres-
sion levels of EGFR and EMT-associated genes, E-cadherin, N-cadherin, 
vimentin and Snail, in OSC-20 and OSC-19 cell lines. TGF-β induced 
EMT-associated gene expression in low-grade invasive OSCC cell lines 
(OSC-20 and OSC-19). The cells were treated with human TGF-β or a con-
trol vehicle for 48 and 72 h. Expression levels are displayed as fold-changes 
relative to the control vehicle at 48 and 72 h, respectively. EGFR, epidermal 
growth factor receptor; EMT, epithelial-mesenchymal transition; OSCC, 
oral squamous cell carcinoma; mRNA, messenger RNA; TGF-β, trans-
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is a loss of EGFR expression in the high-grade invasive 
OSCC line (HOC313 cells). The results of the present study 
suggested that loss of EGFR expression was associated with 
acquirement of an invasive phenotype in OSCC. This poten-
tial association will require further investigation in future 
studies.
The present study analyzed the correlation between 
EGFR expression and the sensitivity to cetuximab using 
3 human OSCC cell lines (OSC-19, OSC-20 and HOC313), 
possessing varying grades of invasive abilities. Variability in 
the responses of certain cell lines to cetuximab treatment was 
identified. Cetuximab was observed to suppress cell growth 
by ~23% in the most treatment-sensitive cell line (OSC-20), 
however, it exerted no effect on the HOC313 cell line. The 
OSC-20 cell line demonstrated a marked increase in EGFR 
mRNA and protein levels compared with the HOC313 cell 
line. However, the HOC313 cell line, which was unaffected 
by cetuximab treatment, demonstrated the lowest levels of 
EGFR expression. When evaluating the affect of EGFR 
expression on the cetuximab treatment responses, a signifi-
cant difference in EGFR expression levels was observed 
between cetuximab-sensitive (OSC-20) and -resistant cells 
(HOC313). Cetuximab-resistant cell lines exhibited reduced 
levels of EGFR expression, indicating that the cetuximab 
treatment response may be dependent on EGFR expression 
status. In addition, increased levels of phosphorylated EGFR 
correlated with cetuximab sensitivity, revealing a potential 
role of activated EGFR in patient responses to cetuximab. A 
previous study has suggested that cells may be sensitive to 
the inhibition of EGFR only if they are dependent on EGFR 
activation for cell survival and growth (31). In agreement with 
these previous results, the levels of phosphorylated EGFR 
have been utilized to predict gefitinib (an EGFR tyrosine 
kinase inhibitor) sensitivity in OSCC patients (32).
The response to EGFR-targeted agents is inversely 
correlated with EMT in multiple tumor types without known 
EGFR mutations, including non-small cell lung cancer, and 
carcinoma of the bladder, colorectal region, pancreas and 
breast (33-37). In the present study, the EMT-associated 
genes, N-cadherin, vimentin and Snail, were upregulated 
in cetuximab-resistant OSCC tumor cells (HOC313). The 
present study additionally demonstrated that TGF-β was able 
to induce a low-grade invasive OSCC cell line (OSC-20) to 
undergo an EMT-associated gene switch, which resulted in 
a loss of EGFR expression. The results of the present study 
indicated that the net effect of TGF-β signaling was the loss 
of EGFR activity, accompanied by a concomitant EMT-asso-
ciated gene switch of tumor cells, as well as acquirement of 
a migratory mesenchymal phenotype. Further studies are 
required in order to elucidate the precise molecular mecha-
nisms underlying the association between EMT and the 
regulation of EGFR expression.
In the present study, it was demonstrated that EGFR status 
affected the response to cetuximab treatments, therefore, 
the level of invasiveness or presence of an EMT phenotype 
may potentially assist in the prediction of EGFR status. 
EMT-associated alterations in gene expression, including 
the upregulation of N-cadherin, vimentin and Snail, have 
additionally been proposed as potential biomarkers for the 
indication of EGFR status and the prediction of patient 
response to cetuximab treatment. However, further in vivo 
studies using clinical samples are required in order to confirm 
these results.
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